Medidata Solutions Inc (NASDAQ:MDSO) – Research analysts at Jefferies Financial Group lowered their FY2019 EPS estimates for Medidata Solutions in a report released on Wednesday, May 1st. Jefferies Financial Group analyst D. Windley now expects that the company will post earnings of $0.78 per share for the year, down from their previous estimate of $0.82.
Several other research analysts have also commented on MDSO. BidaskClub lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $84.60.
Shares of NASDAQ MDSO opened at $93.31 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.57 and a quick ratio of 2.71. Medidata Solutions has a 12 month low of $60.10 and a 12 month high of $98.60. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 97.20, a P/E/G ratio of 8.33 and a beta of 1.42.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.45 EPS for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The company had revenue of $173.50 million during the quarter, compared to analyst estimates of $172.12 million. During the same period in the prior year, the business posted $0.40 EPS. The firm’s revenue was up 16.3% compared to the same quarter last year.
In other news, EVP Daniel Patrick Shannon sold 19,725 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $75.17, for a total value of $1,482,728.25. Following the sale, the executive vice president now directly owns 70,497 shares of the company’s stock, valued at approximately $5,299,259.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Rouven Bergmann sold 12,512 shares of the company’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $75.00, for a total transaction of $938,400.00. The disclosure for this sale can be found here. Insiders sold a total of 47,237 shares of company stock valued at $3,568,628 over the last 90 days. Company insiders own 4.70% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Securian Asset Management Inc grew its position in shares of Medidata Solutions by 1.5% in the 1st quarter. Securian Asset Management Inc now owns 7,587 shares of the company’s stock worth $556,000 after buying an additional 113 shares during the period. Cigna Investments Inc. New grew its position in shares of Medidata Solutions by 4.3% in the 4th quarter. Cigna Investments Inc. New now owns 4,313 shares of the company’s stock worth $291,000 after buying an additional 178 shares during the period. Stephens Inc. AR grew its position in shares of Medidata Solutions by 8.7% in the 4th quarter. Stephens Inc. AR now owns 2,722 shares of the company’s stock worth $184,000 after buying an additional 218 shares during the period. Front Row Advisors LLC grew its position in shares of Medidata Solutions by 1.7% in the 4th quarter. Front Row Advisors LLC now owns 13,043 shares of the company’s stock worth $879,000 after buying an additional 220 shares during the period. Finally, BB&T Corp grew its position in shares of Medidata Solutions by 5.2% in the 4th quarter. BB&T Corp now owns 5,012 shares of the company’s stock worth $338,000 after buying an additional 246 shares during the period.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Story: Special Dividends
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.